Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SION
SELLSionna Therapeutics, Inc. · Healthcare · United States · $2.1B · Avg Vol: $25M/d
COMPANY DESCRIPTION
Sionna Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing novel small molecule therapeutics for cystic fibrosis (CF), aiming to restore function to the critical CFTR protein. Its competitive moat lies in an innovative scientific approach that targets distinct mechanisms to restore CFTR function, potentially offering superior benefits or reaching patient populations underserved by current therapies. Sionna is focused on delivering best-in-class or first-in-class treatments for this specific genetic disorder.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 3.0M | — |
| EPS | -2.32 | -1.70 | -1.45 | -1.88 | — | -1.72 | -2.54 | -2.80 | — |
| Shares | 42.4M | 42.4M | 42.4M | 44.7M | +5.4% | 45.2M | — | — | — |
| Debt | 0 | 10.5M | 9.7M | 8.7M | -9.0% | 8.4M | — | — | — |
| Equity | -69.9M | -114.9M | -163.7M | 306.8M | — | — | — | — | — |
| Op CF | -36.1M | -43.7M | -52.8M | -66.3M | — | -71.8M | — | — | — |
| Inv CF | -29.3M | 27.4M | -126.9M | -118.7M | — | — | — | — | — |
| Fin CF | 110.9M | 31.0K | 179.0M | 205.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SION are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SION | Sionna Therapeutics, Inc.(you) | $2.1B | 28 | SELL |
| NUVB | Nuvation Bio Inc. | $2.2B | 28 | SELL |
| PVLA | Palvella Therapeutics, Inc. | $2.0B | 30 | SELL |
| STOK | Stoke Therapeutics, Inc. | $1.8B | 27 | SELL |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.9B | 24 | SELL |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.6B | 28 | SELL |
| NRIX | Nurix Therapeutics, Inc. | $2.4B | 30 | SELL |
| KOD | Kodiak Sciences Inc. | $2.6B | 27 | SELL |
| RAPP | Rapport Therapeutics, Inc. | $1.9B | 33 | SELL |
| AGIO | Agios Pharmaceuticals, Inc. | $2.2B | 34 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%